Metabolic / fat-loss

Peptides and related compounds marketed for fat loss and metabolic health. Evidence ranges from investigational amylin analogues to preclinical-only agents; several fat-loss claims are not supported by human data.

Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.

5 peptides

Cagrilintide

Human observational

AM833, part of CagriSema

An investigational long-acting amylin analogue, studied alone and combined with semaglutide (CagriSema). Not yet approved.

AOD-9604

Animal / preclinical

hGH fragment 176-191

A modified fragment of human growth hormone marketed for fat loss. Human trials did not demonstrate meaningful weight loss.

MOTS-c

Animal / preclinical

Mitochondrial ORF of the 12S rRNA-c

A mitochondrial-derived peptide studied for metabolic and exercise-mimetic effects, largely in animals. Human evidence is limited.

5-Amino-1MQ

Animal / preclinical

A small-molecule NNMT inhibitor (not strictly a peptide) marketed for fat loss and metabolism. Evidence is preclinical.

Adipotide

Animal / preclinical

FTPP, Prohibitin-targeting peptide

An experimental targeted peptide designed to kill the blood supply of fat tissue. It produced weight loss in obese primates but also caused kidney toxicity, and it has not progressed to approved human use.